drugset
drugset / Trial / NCT04873323

A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

NCT04873323 ↗

Phase 1 Completed 59 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedCrossoverDouble-blindTreatment

Summary

A clinical study to evaluate the effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects

Timeline

Start
2021-06-07
Primary completion
2021-09-28
Completion
2021-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg —
Subject TS-142 Small molecule 10 mg Oral
Subject TS-142 Small molecule 30 mg Oral

Indications

No indication recorded.